Abstract 966P
Background
Hepatocellular carcinoma (HCC) represents the third most deadly cancer worldwide with still high therapeutic failure and recurrence rates mainly associated with the late diagnosis and the molecular heterogeneity of this liver tumor. The transmembrane glycoprotein neuropilin-1 (NRP1) has shown a key role in the modulation of tumor-associated signaling pathways and processes by interacting with key receptor tyrosine kinases. Nonetheless, few studies have evaluated the potential value of NRP1 as a tumor biomarker or therapeutic target in HCC. For this reason, we aimed at assessing the clinical significance of the receptor NRP1 in the prognosis, diagnosis and other tumor-associated features in HCC patients.
Methods
We conducted a systematic review with meta-analysis including all the articles published up to May 31st 2022 that evaluated the clinical correlation of NRP1 overexpression with tumor prognosis, development and/or other clinicopathological features in patients diagnosed with HCC. An exhaustive literature search was performed in five online databases, selecting potential papers to be included based on predefined eligibility criteria. Data from included studies were extracted or estimated by Parmar method and meta-analyzed employing the STATA 16 software.
Results
A total of 1305 patients from seven studies were included in the quantitative analysis, showing approximately 53.81% of patients NRP1 overexpression. After meta-analysis, higher levels of NRP1 proved to be significantly correlated to poor prognosis, represented by lower overall survival (OS). Moreover, a significant association with tumor pathogenesis was also found by observing higher NRP1 expression in tumor tissue samples from 692 HCC patients. Finally, a marked correlation was obtained between increased NRP1 expression and patient’s age, younger than 50 years old, and a higher risk of venous invasion, highlighting the potential of NRP1 as a tumor biomarker in HCC.
Conclusions
Overall, these results suggest that NRP1 have a potential role for prognosis, development and risk of invasion, and, therefore, could constitute a valuable biomarker in patients diagnosed with HCC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
CIBERehd is funded by Instituto de Salud Carlos III (ISCIII), Spain.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
978P - Post-progression outcomes of advanced HCC patients (aHCC pts) treated with first-line atezolizumab/bevacizumab (A/B)
Presenter: Claudia Fulgenzi
Session: Poster session 18
979P - Safety interim analyses of first-line systemic therapy with atezolizumab plus bevacizumab (ATZ+BEV) in patients from Spain with unresectable hepatocellular carcinoma (HCC): Phase IIIb ATHECA
Presenter: Maria Elisa Reig Monzon
Session: Poster session 18
980P - Neutrophil count predicts the complete response after transarterial chemoembolization related to favorable outcome in hepatocellular carcinoma
Presenter: Young Mi Hong
Session: Poster session 18
981P - The response of portal vein tumoral thrombosis to moderately hypo-fractionated radiotherapy using intensity modulated radiotherapy
Presenter: Ahmad Abdel-Azeez
Session: Poster session 18
982P - Transarterial chemoembolization with idarubicin versus epirubicin for hepatocellular carcinoma: An interim analysis of a multicentre, randomized controlled phase III trial
Presenter: Zhewei Zhang
Session: Poster session 18
983P - Safety and efficacy of durvalumab plus hepatic artery infusion chemotherapy in HCC with severe portal vein tumor thrombosis (Vp3/4) – the DurHope study
Presenter: Ming Zhao
Session: Poster session 18
984P - Comparative study of scoring systems predicting outcome of transarterial chemoembolization for hepatocellular carcinoma: A nationwide cohort study
Presenter: Jo Kook Lee
Session: Poster session 18
987P - Safety and efficacy of lenvatinib in patients with unresectable hepatocellular carcinoma (uHCC) in real-world practice in Korea
Presenter: Wonseok Kang
Session: Poster session 18
988P - Burden of primary liver cancer in the Middle East and North Africa Region from 1990 to 2019
Presenter: Ahmed Hafez Allam
Session: Poster session 18